ST Renfu Announcement: The company plans to issue A-shares to specific investors in 2026, raising a total amount of no less than RMB 3 billion and no more than RMB 3.5 billion. The net proceeds after deducting related issuance costs will be used for innovative drug R&D projects—subsidiary Yichang Renfu Project, headquarters research institute project, gender health and complex formulation manufacturing base construction projects, digital intelligence construction project, and to supplement working capital. The target investor is the company’s controlling shareholder, China Merchants Shengke. The issuance price is RMB 14.95 per share, with the number of shares issued not less than 201 million and not more than 234 million.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
ST Renfu: Plans to raise no more than 3.5 billion yuan through additional issuance
ST Renfu Announcement: The company plans to issue A-shares to specific investors in 2026, raising a total amount of no less than RMB 3 billion and no more than RMB 3.5 billion. The net proceeds after deducting related issuance costs will be used for innovative drug R&D projects—subsidiary Yichang Renfu Project, headquarters research institute project, gender health and complex formulation manufacturing base construction projects, digital intelligence construction project, and to supplement working capital. The target investor is the company’s controlling shareholder, China Merchants Shengke. The issuance price is RMB 14.95 per share, with the number of shares issued not less than 201 million and not more than 234 million.